Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124,193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
Berenson JR, Limon A, Rice S, Safaie T, Boccia R, Yang H, Moezi M, Lim S, Schwartz G, Eshaghian S, Brobeck M, Swift R, Eades BM, Bujarski S, Sebhat Y, Ray R, Kim S, Del Dosso A, Vescio R. Berenson JR, et al. Among authors: kim s. Target Oncol. 2024 May;19(3):343-357. doi: 10.1007/s11523-024-01049-w. Epub 2024 Apr 20. Target Oncol. 2024. PMID: 38643346 Clinical Trial.
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma.
Goldwater MS, Stampfer SD, Sean Regidor B, Bujarski S, Jew S, Chen H, Xu N, Kim C, Kim S, Berenson JR. Goldwater MS, et al. Among authors: kim c, kim s. Clin Infect Pract. 2023 Jan;17:100214. doi: 10.1016/j.clinpr.2022.100214. Epub 2022 Dec 13. Clin Infect Pract. 2023. PMID: 36530752 Free PMC article.
Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression-A single center retrospective study.
Regidor BS, Jew S, Goldwater MS, Beatty BM, Bujarski S, ElSayed A, Danis R, Kim S, Swift R, Schwartz G, Berenson JR. Regidor BS, et al. Among authors: kim s. Eur J Haematol. 2023 Oct;111(4):628-635. doi: 10.1111/ejh.14057. Epub 2023 Jul 24. Eur J Haematol. 2023. PMID: 37485542
Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody.
Regidor BS, Siddiqi D, Beatty BM, Goldwater MS, Jew S, Bujarski S, Swift R, Kim S, Berenson JR. Regidor BS, et al. Among authors: kim s. Eur J Haematol. 2023 Feb;110(2):222-223. doi: 10.1111/ejh.13896. Epub 2022 Nov 20. Eur J Haematol. 2023. PMID: 36367357 No abstract available.
ZIC1 is a context-dependent medulloblastoma driver in the rhombic lip.
Lee JJY, Tao R, You Z, Haldipur P, Erickson AW, Farooq H, Hendriske LD, Abeysundara N, Richman CM, Wang EY, Das Gupta N, Hadley J, Batts M, Mount CW, Wu X, Rasnitsyn A, Bailey S, Cavalli FMG, Morrissy S, Garzia L, Michealraj KA, Visvanathan A, Fong V, Palotta J, Suarez R, Livingston BG, Liu M, Luu B, Daniels C, Loukides J, Bendel A, French PJ, Kros JM, Korshunov A, Kool M, Chico Ponce de León F, Perezpeña-Diazconti M, Lach B, Singh SK, Leary SES, Cho BK, Kim SK, Wang KC, Lee JY, Tominaga T, Weiss WA, Phillips JJ, Dai S, Zadeh G, Saad AG, Bognár L, Klekner A, Pollack IF, Hamilton RL, Ra YS, Grajkowska WA, Perek-Polnik M, Thompson RC, Kenney AM, Cooper MK, Mack SC, Jabado N, Lupien M, Gallo M, Ramaswamy V, Suva ML, Suzuki H, Millen KJ, Huang LF, Northcott PA, Taylor MD. Lee JJY, et al. Among authors: kim sk. Nat Genet. 2025 Jan 3. doi: 10.1038/s41588-024-02014-z. Online ahead of print. Nat Genet. 2025. PMID: 39753768
124,193 results
You have reached the last available page of results. Please see the User Guide for more information.